Sandra Horning, MD
The European Commission has granted regulatory approval to atezolizumab (Tecentriq) monotherapy for the treatment of patients with previously-treated locally advanced or metastatic non–small cell lung cancer (NSCLC) and previously-treated locally advanced or metastatic urothelial carcinoma (mUC).
Safety results included pooled data from 2160 patients with mUC or NSCLC. The most common adverse all-grade reactions were fatigue (35.4%), decreased appetite (25.5%), nausea (22.9%), dyspnea (21.8%), diarrhea (18.6%), pyrexia (18.3%), rash (18.6%), vomiting (15.0%), arthralgia (14.2%), asthenia (13.8%), and pruritus (11.3%).
Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer. https://www.roche.com/media/store/releases/med-cor-2017-09-22c.htm. Accessed September 25, 2017.
... to read the full story